1,721,132 research outputs found
Medical research could soon be jeopardized by new european union data protection regulations
No full textBack to the future. the crucial role of clinical registries in the era of randomized controlled trials for identifying the optimal medical therapy of heart failure
Full text linkA way forward to the elimination of conflict of interest for experts involved in regulatory medicine and guidelines
No full textOne must always be aware that external influences may affect the
interpretation of study results, the process of drug approval, and
the economical analyses of pharmaceutical agents. Companies
often have an important say in the definition of the research question,
in the selection of patients, the way of reporting drop-outs, and
adverse events. Furthermore, industry-financed cost-effectiveness
analyses are more likely to support additional expenditures on investigational
drugs than standard treatments.On the other hand, we have to recognize the pivotal role of the
pharmaceutical industry in biomedical research since, given the lack
of public funding, the majority of funded clinical trials in Europe and
in the Americas is supported by industry. There are examples of
government-funded clinical trials that changed the course of a
disease, but they are scanty
Safety and efficacy of ezetimibe: A meta-analysis
No full textThe addition of ezetimibe to statin therapy has been widely demonstrated to significantly reduce low-density lipoprotein cholesterol levels. However, the efficacy of ezetimibe in reducing CV events and its safety has been less investigated. The aim of the current meta-analysis was to report efficacy and safety of ezetimibe from randomized clinical trials
The strategic vision of the 2022-2024 mandate - greater involvement of members, young specialists for an HFA community without borders
No full textRoadmap for the management of heart failure patients during the vulnerable phase after heart failure hospitalizations: how to implement excellence in clinical practice
No full textPatients discharged after an episode of acute heart failure have an increased risk of hospitalizations and deaths within the subsequent 3 months. This phase is commonly called the 'vulnerable period' and it represents a window of opportunity of intervention in order to improve longer term outcomes. Prompt identification of signs of residual haemodynamic congestion is a priority in planning for the out-of-hospital management strategies. Patients will also need to be screened for frailty and have a prioritization of the management of their comorbidities. Life-saving medications should be started together or in a short time and up-titrated (when needed) according to blood pressure, heart rate and concomitant comorbidities. Ideally, patients should be assessed by their general practitioner within 1 week of discharge and have a hospital/clinic follow-up within 4 weeks of discharge. Patients should progressively resume physical activities and adhere to an educational programme with appropriate lifestyle adjustments best implemented during a cardiac rehabilitation programme
Continuous 12-lead ST-segment monitoring improves identification of low-risk patients with chest pain and a worse in-hospital outcome
No full textVarious strategies have been proposed to improve diagnosis and triage of patients with chest pain at low risk, but uncertainty still exists on the optimal combination of diagnostic tools that should be used in this subset of patients
Adaptive licensing - A way forward in the approval process of new therapeutic agents in Europe
No full text
[Treatment of heart failure with sodium-glucose cotransporter 2 inhibitors across the spectrum of left ventricular function]
No full text- …
